NPCE
NeuroPace, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$14.90
+1.02%Aug 11, 2026, 22:26 UTC
NeuroPace, Inc. reported a second-quarter loss of $0.18 per share, beating the Zacks Consensus Estimate of a $0.19 loss and improving from a $0.26 loss a year earlier.
Jul 28, 2026, 20:01 UTC
NeuroPace received FDA guidance on its PMA supplement seeking to expand the RNS System's indication to include idiopathic generalized epilepsy.
Jun 2, 2026, 16:51 UTC
NeuroPace (NPCE) received FDA approval for its AI-powered ECoG Assistant for epilepsy.
Source: